A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The intracellular distribution of a drug can cause significant variability in both activity and selectivity. Herein, we investigate the mechanism by which the anti-cancer agents, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and the clinically trialed, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), re-instate the efficacy of doxorubicin (DOX), in drug-resistant P-glycoprotein (Pgp)-expressing cells. Both Dp44mT and DpC potently target and kill Pgp-expressing tumors, while DOX effectively kills non-Pgp-expressing cancers. Thus, the combination of these agents should be considered as an effective rationalized therapy for potently treating advanced and resistant tumors that are often heterogeneous in terms of Pgp-expression. These studies demonstrate that both Dp44mT and DpC are transported into lysosomes via Pgp transport activity, where they induce lysosomal-membrane permeabilization to release DOX trapped within lysosomes. This novel strategy of loading lysosomes with DOX, followed by permeabilization with Dp44mT or DpC, results in the relocalization of stored DOX from its lysosomal 'safe house' to its nuclear targets, markedly enhancing cellular toxicity against resistant tumor cells. Notably, the combination of Dp44mT or DpC with DOX showed a very high level of synergism in multiple Pgp-expressing cell types, for example, cervical, breast and colorectal cancer cells. These studies revealed that the level of drug synergy was proportional to Pgp activity. Interestingly, synergism was ablated by inhibiting Pgp using the pharmacological inhibitor, Elacridar, or by inhibiting Pgp-expression using Pgp-silencing, demonstrating the importance of Pgp in the synergistic interaction. Furthermore, lysosomal-membrane stabilization inhibited the relocalization of DOX from lysosomes to the nucleus upon combination with Dp44mT or DpC, preventing synergism. This latter observation demonstrated the importance of lysosomal-membrane permeabilization to the synergistic interaction between these agents. The synergistic and potent anti-tumor efficacy observed between DOX and thiosemicarbazones represents a promising treatment combination for advanced cancers, which are heterogeneous and composed of non-Pgp- and Pgp-expressing tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 3×
“(b) Combination index (CI) values of the drug combinations between (i) DOX (72 h/37 °C) and Dp44mT (24 h/37 °C), (ii) DOX (72 h/37 °C) and DpC (24 h/37 °C), as measured by the Chou-Talalay method.(25,29) CI41 Antagonism, CI= 1 Additive, CIo1 Synergistic.”
MethodMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“A major limitation of the cytotoxic chemotherapeutic, Doxorubicin (DOX; Figure 1ai), is resistance caused by drug-resistance pumps, for example, P-glycoprotein (Pgp).(1,2) This has been attributed to both Pgp-mediated drug efflux through the plasma membrane(3) and also due to increased Pgp-mediated drug trapping withi…”
BackgroundCellular injury induced by oxidative stress is mediated through lysosomal damage
Öllinger, K., & Brunk, U. T. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)00062-3 · Cited by 243 · cited 2×
“Under control conditions, KBV1 (+Pgp) cells showed the distinct punctate AO red pattern (Figure 5ai), indicating intact lysosomes.(38) Treatment with Cu[Dp44mT] (30 μM/30 min/37 °C) or Cu[DpC] (15 μM/30 min/37 °C) markedly and significantly (Po0.”
BackgroundSensitivity to Lysosome-Dependent Cell Death Is Directly Regulated by Lysosomal Cholesterol Content
Appelqvist, H., Sandin, L., Björnström, K., Saftig, P., Garner, B., Öllinger, K., & Kågedal, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050262 · Cited by 108 · cited 2×
“We attribute this effect to U18666A stabilizing lysosomal membranes against oxidative stress and also partially inhibiting Pgp activity (Figure 7aiii and aiv), thereby preventing LMP (Figure 8).(14,35) The ability of U18666A to inhibit LMP by Dp44mT or DpC prevents DOX release from lysosomes and avoids nuclear targeti…”
BackgroundResult
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Various studies have shown that LMP inducers like chloroquine (CQ) can result in resistant cancer cell death by releasing sequestered drugs and proteasomes like cathepsin to act on the nucleus and induce apoptosis [220–222].”
BackgroundAltered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Brown, R. A. M., Richardson, K. L., Kabir, T. D., Trinder, D., Ganss, R., & Leedman, P. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00476 · Cited by 278
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Metadata
- Authors
- Seebacher, N. A., Richardson, D. R., & Jansson, P. J.
- Venue
- Cell Death & Disease
- Published
- 2016-12-01
- Volume
- 7
- Issue
- 12
- Pages
- e2510-e2510
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2558188837
- Cited by
- 111
- References
- 6
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. https://app.cochat.ai/papers/10.1038/cddis.2016.381
- The paper
- Seebacher, N. A., Richardson, D. R., & Jansson, P. J. (2016). A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death & Disease. https://doi.org/10.1038/cddis.2016.381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.